We are live on ! Find out more
ORKA

Oruka Therapeutics
ORKA

11 hedge funds and large institutions have $1.54M invested in Oruka Therapeutics in 2014 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% less funds holding

Funds holding: 14 → 11 (-3)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

43% less capital invested

Capital invested by funds: $2.68M → $1.54M (-$1.14M)

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

Holders
11
Holders Change
-3
Holders Change %
-21.43%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
3
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$412K
2
VKH
Virtu KCG Holdings
New York
+$140K
3
Morgan Stanley
Morgan Stanley
New York
+$58.4K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$49.7K
5
AL
Airain Ltd
Guernsey
+$23.4K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$1.03M
2
Deutsche Bank
Deutsche Bank
Germany
-$589K
3
DS
DRW Securities
Illinois
-$168K
4
Northern Trust
Northern Trust
Illinois
-$53K
5
TRCT
Tower Research Capital (TRC)
New York
-$20.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$721K +$412K +141 +123%
BCM
2
Bridgeway Capital Management
Texas
$223K – – –
Morgan Stanley
3
Morgan Stanley
New York
$160K +$58.4K +20 +54%
VKH
4
Virtu KCG Holdings
New York
$133K +$140K +48 New
Bank of America
5
Bank of America
North Carolina
$124K -$8.77K -3 -6%
HighTower Advisors
6
HighTower Advisors
Illinois
$66K -$11.7K -4 -14%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$47K +$49.7K +17 New
RCM
8
Rotella Capital Management
Washington
$24K +$23.4K +8 New
AL
9
Airain Ltd
Guernsey
$22K +$23.4K +8 New
BA
10
BlackRock Advisors
Delaware
$10K – – –
TRCT
11
Tower Research Capital (TRC)
New York
$8K -$20.5K -7 -70%
Renaissance Technologies
12
Renaissance Technologies
New York
– -$1.03M -407 Closed
Deutsche Bank
13
Deutsche Bank
Germany
– -$589K -232 Closed
DS
14
DRW Securities
Illinois
– -$168K -66 Closed
Northern Trust
15
Northern Trust
Illinois
– -$53K -21 Closed
FNYS
16
First New York Securities
New York
– -$14K -5 Closed
California Public Employees Retirement System
17
California Public Employees Retirement System
California
– -$3K -1 Closed
Nomura Holdings
18
Nomura Holdings
Japan
– -$2K -1 Closed

ORKA Hedge Fund Activity: Q1 2014 in Review

11 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q1 2014, worth a combined $1.54M — down 43% from $2.68M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of ORKA and 4 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Vanguard Group, adding an estimated $412K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $1.03M sold.

  • 11 institutional investors held Oruka Therapeutics (ORKA) as of Q1 2014, down from 14 in Q4 2013.
  • Funds reported $1.54M of Oruka Therapeutics stock for Q1 2014, down 43% quarter-over-quarter.
  • 4 funds opened new Oruka Therapeutics positions in Q1 2014 and 7 closed out, a net change of -3 holders.
  • The largest Oruka Therapeutics buyer in Q1 2014 was Vanguard Group, an estimated $412K added.
  • The largest Oruka Therapeutics seller in Q1 2014 was Renaissance Technologies, an estimated $1.03M sold.

Based on aggregated 13F filings for Q1 2014.